Inovio Pharmaceuticals Inc. recently stated that its pre-clinical testing for the company’s synthetic vaccine designed to protect people from the Zika virus has shown a robust, durable immune response in test subjects.
This demonstrates that there is significant evidence that supports a SynCon vaccine to protect people from the Zika virus.
There have been serious autoimmune and neurological complications that are related to Zika virus. These complications include microcephaly in newborns and Guillain-Barre syndrome.
The study used constructs from DNA vaccines to target several antigens of the Zika virus. These were synthetically created with the SynCon vaccine technology from Inovio. Researchers then delivered these into the subjects with Cellectra electroporation delivery technology.
"Using our SynCon technology we rapidly generated a synthetic vaccine candidate that shows promise as a preventive and treatment,” Inovio President and CEO J. Joseph Kim said. “With robust antibody and killer T cell responses generated by our vaccine in mice, we will next test the vaccine in non-human primates and initiate clinical product manufacturing. We plan to initiate phase I human testing of our Zika vaccine before the end of 2016."
Inovio created the vaccine in collaboration with GeneOne Life Sciences as well as academic partners.